 |
 |
 |
 |
Cytoprotection
FibroGen is developing small molecules that activate HIF-mediated
responses to situations when tissues or organs are deprived of oxygen
and nutrients, resulting in tissue damage and cell death. FibroGen's HIF
activation approach has been demonstrated to be effective in upregulating
multiple cytoprotective factors that promote cell survival and preserve
organ function in preclinical models of renal ischemia reperfusion injury,
radiocontrast nephrotoxicity, myocardial infarction, and ischemic
stroke. FibroGen is also pursuing HIF-cytoprotection as a means of
treating the pain crises characteristic of sickle cell disease.
|
|
|
|
